Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study

被引：7

作者：

Cohen, Jonathon B. ^{[1
]}

Kuruvilla, John ^{[2
,3
]}

Engert, Andreas ^{[4
]}

Ansell, Stephen M. ^{[5
]}

Younes, Anas ^{[6
]}

Lee, Hun Ju ^{[7
]}

Trneny, Marek ^{[8
,9
]}

Savage, Kerry J. ^{[10
]}

Ramchandren, Radhakrishnan ^{[11
]}

Collins, Graham P. ^{[12
]}

Zinzani, Pier Luigi ^{[13
]}

De Boer, Jan Paul ^{[14
]}

Shipp, Margaret A. ^{[15
]}

Santoro, Armando ^{[16
]}

Timmerman, John M. ^{[17
]}

Sacchi, Mariana ^{[18
]}

Sy, Oumar ^{[18
]}

Armand, Philippe ^{[19
]}

机构：

[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[2] Univ Toronto, Toronto, ON, Canada

[3] Princess Margaret Canc Ctr, Toronto, ON, Canada

[4] Univ Hosp Cologne, Cologne, Germany

[5] Mayo Clin, Rochester, MN USA

[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[8] Charles Univ Prague, Prague, Czech Republic

[9] Gen Univ Hosp Prague, Prague, Czech Republic

[10] British Columbia Canc, Vancouver, BC, Canada

[11] Barbara Ann Karmanos Canc Inst, Detroit, MI USA

[12] Churchill Hosp, Oxford Canc & Haematol Ctr, Oxford, England

[13] Univ Bologna, Inst Hematol L e A Seragnoli, Bologna, Italy

[14] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands

[15] Dana Farber Canc Inst, Ctr Hematol Oncol, Boston, MA 02115 USA

[16] Humanitas Univ, Humanitas Canc Ctr, Rozzano Milan, Italy

[17] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA

[18] Bristol Myers Squibb, Princeton, NJ USA

[19] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-114502

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2932

引用

页数：4

共 50 条

[21] CHECKMATE 205: A PHASE 2 STUDY OF NIVOLUMAB IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION AND BRENTUXIMAB VEDOTIN
Engert, A.
Santoro, A.
Shipp, M.
Zinzani, P. L.
Timmerman, J.
Ansell, S.
Armand, P.
Fanale, M.
Ratanatharathorn, V.
Kuruvilla, J.
Cohen, J.
Collins, G.
Savage, K.
Trneny, M.
Kato, K.
Farsaci, B.
Parker, S.
Rodig, S.
Younes, A.
HAEMATOLOGICA, 2016, 101 : 319 - 319
[22] Patient Subgroup Analysis of Quality-of-Life Outcomes in Checkmate 205, a Phase 2 Study of Nivolumab in Patients with Classical Hodgkin Lymphoma
Engert, Andreas
Taylor, Fiona
Bennett, Bryan
Hirji, Ishan
Cocks, Kim
McDonald, Jeffrey
Mann, Erin
Kato, Kazunobu
Cella, David
BLOOD, 2016, 128 (22)
[23] NIVOLUMAB PLUS DOXORUBICIN, VINBLASTINE AND DACARBAZINE FOR NEWLY DIAGNOSED ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA: 2-YEAR FOLLOW-UP IN THE CHECKMATE 205 STUDY
Domingo-Domenech, E.
Ramchandren, R.
Rueda, A.
Trne
Ny, M.
Feldman, T.
Hun, Lee J.
Provencio, M.
Sillaber, C.
Cohen, J. B.
Savage, K. J.
Willenbacher, W.
Sumbul, A.
Sacchi, M.
Armand, P.
Ansell, S.
HAEMATOLOGICA, 2019, 104 : 21 - 22
[24] Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study
Ramchandren, Radhakrishnan
Fanale, Michelle A.
Rueda, Antonio
Armand, Philippe
Trneny, Marek
Feldman, Tatyana A.
Ansell, Stephen M.
Provencio, Mariano
Jaeger, Ulrich
Cohen, Jonathon B.
Savage, Kerry J.
Willenbacher, Wolfgang
Sacchi, Mariana
Sumbul, Anne
Domenech, Eva Domingo
BLOOD, 2017, 130
[25] Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
Maruyama, Dai
Terui, Yasuhito
Yamamoto, Kazuhito
Fukuhara, Noriko
Choi, Ilseung
Kuroda, Junya
Ando, Kiyoshi
Hattori, Akira
Tobinai, Kensei
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (11) : 1265 - 1273
[26] PENPULIMAB FOR RELAPSED/REFRACTORY (R/R) CLASSICAL HODGKIN'S LYMPHOMA (CHL): EXTENDED FOLLOW-UP OF THE MULTICENTER, SINGLE-ARM, PHASE 2 STUDY
Song, Yuqin
Zhou, Keshu
Jin, Chuan
Qian, Zhengzi
Hou, Ming
Fan, Lei
Li, Fei
Ding, Kaiyang
Zhou, Hui
Li, Xiaoling
Chen, Bing
Sun, Xiuhua
Song, Xianmin
Jiang, Ming
Zhang, Qingyuan
Liu, Lihong
Yu, Guohua
Hu, Yu
Zhao, Zheng
Liu, Ligen
Xue, Hongwei
Luo, Jun
He, Bai
Yao, Zhifang
Xu, Fenghua
Zhao, Min
Li, Baiyong
Xia, Yu
Zhu, Jun
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A598 - A598
[27] QUALITY-OF-LIFE OUTCOMES IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA TREATED WITH NIVOLUMAB MONOTHERAPY IN CHECKMATE 205 (COHORT B), A PHASE 2 STUDY
Engert, A.
Hirji, I.
Taylor, F.
Bennett, B.
Cocks, K.
Kato, K.
Cella, D.
HAEMATOLOGICA, 2016, 101 : 73 - 73
[28] Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial (vol 36, pg 1428, 2018)
Armand
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (26) : 2748 - 2748
[29] Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma
Armand, Philippe
Janssens, Ann
Gritti, Giuseppe
Radford, John
Timmerman, John
Pinto, Antonio
Vilchez, Santiago Mercadal
Johnson, Peter
Cunningham, David
Leonard, John P.
Rodig, Scott J.
Martin-Regueira, Patricia
Sumbul, Anne
Samakoglu, Selda
Tang, Hao
Ansell, Stephen M.
BLOOD, 2021, 137 (05) : 637 - 645
[30] CheckMate 436: Extended Follow-Up from the Phase 2 Study Investigating Nivolumab Plus Brentuximab Vedotin (BV) for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (R/R PMBL)
Zinzani, Pier Luigi
Santoro, Armando
Gritti, Giuseppe
Brice, Pauline
Barr, Paul
Cunningham, David
Kline, Justin
Johnson, Nathalie
Mehta-Shah, Neha
Fanale, Michelle
Francis, Stephen
Moskowitz, Alison
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S398 - S399

← 1 2 3 4 5 →